Considerable progress has been made in the past several years in the scientific
understanding of, and available treatments for, acute myeloid leukemia (AML). Achievement …

The consensus in 2018 from The Chinese Society of Haematology (CSH) on the monitoring,
treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell …

Half a century ago, the common occurrence of relapses in patients with acute myeloid
leukemia (AML) after achieving a morphologic remission, together with the inverse linear …

Measurable residual disease (MRD) assessment is incorporated in the clinical decision-
making of acute myeloid leukemia (AML) because of its prognostic value. 1 Therefore …

Minimal residual disease (MRD) is a well-established prognostic marker that allows
subdivision of AML patients into different risk groups independently of the methods being …

Approximately 90% of patients with myelodysplastic syndromes (MDSs) have somatic
mutations that are known or suspected to be oncogenic in the malignant cells. The genetic …

Patient-and leukemia-specific factors assessed at diagnosis classify patients with acute
myeloid leukemia (AML) in risk categories that are prognostic for outcome. The induction …

Simple Summary Acute myeloid leukemia (AML) is an aggressive blood cancer disease that
can only be cured by intensive anticancer treatment, and for several patients, allogeneic …

Measurable residual disease (MRD)-testing is used in many haematological cancers to
estimate relapse risk and to direct therapy. Sometimes MRD-test results are used for …

In recent years, major advances in the understanding of acute myeloid leukemia (AML)
pathogenesis, together with technological progress, have led us into a new era in the …